(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Interstitial Lung Disease pipeline constitutes 120+ key companies continuously working towards developing 120+ Interstitial Lung Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. 

 

“Interstitial Lung Disease Pipeline Insight, 2023″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Lung Disease Market.

 

To know more about Interstitial Lung Disease pipeline report, click here @ Interstitial Lung Disease Pipeline Analysis

 

Some of the key takeaways from the Interstitial Lung Disease Pipeline Report:

• Interstitial Lung Disease Companies across the globe are diligently working toward developing novel Interstitial Lung Disease treatment therapies with a considerable amount of success over the years. 
• Leading Interstitial Lung Disease companies working in the treatment market are  AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Blade Therapeutics, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics,  Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, others, are developing therapies for the Interstitial Lung Disease treatment 

• Emerging Interstitial Lung Disease therapies such as – AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Cudetaxestat, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation,  Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others. 
• In March 2022, Blade Therapeutics, announced new data from preclinical studies that highlight the differentiating characteristics of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases. Cudetaxestat (BLD-0409), a non-competitive, reversible inhibitor of autotaxin, has demonstrated direct anti-fibrotic activity and differentiating preclinical and biochemical characteristics which support the potential for a treatment profile in lung and liver fibrosis. Cudetaxestat has been granted orphan drug designations in the treatment of IPF and systemic sclerosis.
• In February 2022, Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF). BI 1015550 is an oral, phosphodiesterase 4B (PDE4B) inhibitor with the potential to address both pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs)
• In February 2022, Endeavor BioMedicines, announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners.Proceeds will support the advancement of Endeavor’s pipeline programs, including ENV-101 (taladegib), a small molecule inhibitor of the PTCH1 receptor in the Hedgehog signaling pathway for the treatment of cancer and idiopathic pulmonary fibrosis (IPF), as well as ENV-201, a potentially best-in-class small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers

 

Interstitial Lung Disease Overview

Interstitial lung disease is a chronic (long-term) lung condition. It occurs as a result of injury between the air sacs in the lung. The scarring of the lung creates breathing difficulties. Interstitial lung disease causes breathlessness and a dry cough during exercise. These problems may worsen gradually or rapidly. The cause of interstitial lung disease is unknown; however, inhaling environmental or occupational pollutants such as inorganic or organic dust is thought to be a major contributing factor.

The primary interstitial lung disease symptoms are dry cough and shortness of breath at rest or aggravated by exertion. The interstitial lung disease diagnosis tests include- Chest X-ray, Lung function test, CT scan, and lung biopsy. 

 

Get a Free Sample PDF Report to know more about Interstitial Lung Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight

 

Emerging Interstitial Lung Disease Drugs Under Different Phases of Clinical Development Include:

• RO-0220912: Roche
• ATYR1923: aTyr Pharma
• BI 1015550: Boehringer Ingelheim
• Pamrevlumab: FibroGen
• Zinpentraxin alfa: Roche
• LT 0011: LTT Bio-Pharma
• Abatacept: Bristol-Myers Squibb
• PRA023: Prometheus Biosciences
• Yifenidon: HEC Pharm
• Riociguat: Bayer
• Treprostinil Palmitil: Insmed
• BMS 986278: Bristol-Myers Squibb
• Pirfenidone inhalation: Avalyn Pharma
• Deupirfenidone: PureTech Health
• IanalumabL: Novartis

 

Route of Administration

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical  

 

Interstitial Lung Disease Pipeline Therapeutics Assessment

• Interstitial Lung Disease Assessment by Product Type
• Interstitial Lung Disease By Stage and Product Type
• Interstitial Lung Disease Assessment by Route of Administration
• Interstitial Lung Disease By Stage and Route of Administration
• Interstitial Lung Disease Assessment by Molecule Type
• Interstitial Lung Disease by Stage and Molecule Type

 

DelveInsight’s Interstitial Lung Disease Report covers around 120+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Further Interstitial Lung Disease product details are provided in the report. Download the Interstitial Lung Disease pipeline report to learn more about the emerging Interstitial Lung Disease therapies- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight

 

Interstitial Lung Disease Pipeline Analysis:

The Interstitial Lung Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Interstitial Lung Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Lung Disease Treatment.
• Interstitial Lung Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Interstitial Lung Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Interstitial Lung Disease market.

 

Download Sample PDF Report to know more about Interstitial Lung Disease drugs and therapies- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight

 

Scope of Interstitial Lung Disease Pipeline Drug Insight    

• Coverage: Global
• Key interstitial lung disease Companies: AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Blade Therapeutics, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics,  Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, others
• Key interstitial lung disease Pipeline Therapies: AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Cudetaxestat, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation,  Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.

 

Request for Sample PDF Report for Interstitial Lung Disease Pipeline Assessment and clinical trials – https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight

 

Table of Contents

1	Interstitial Lung Disease Report Introduction
2	Interstitial Lung Disease Executive Summary
3	Interstitial Lung Disease Overview
4	Interstitial Lung Disease- Analytical Perspective In-depth Commercial Assessment
5	Interstitial Lung Disease Pipeline Therapeutics
6	Interstitial Lung Disease Late Stage Products (Phase II/III)
7	Interstitial Lung Disease Mid Stage Products (Phase II)
8	Interstitial Lung Disease Early Stage Products (Phase I)
9	Interstitial Lung Disease Preclinical Stage Products
10	Interstitial Lung Disease Therapeutics Assessment
11	Interstitial Lung Disease Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Interstitial Lung Disease Key Companies
14	Interstitial Lung Disease Key Products
15	Interstitial Lung Disease Unmet Needs
16	Interstitial Lung Disease Market Drivers and Barriers
17	Interstitial Lung Disease Future Perspectives and Conclusion
18	Interstitial Lung Disease Analyst Views
19	Appendix
20	About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting